Primary Biliary Cholangitis Therapeutics Market, Global Outlook and Forecast 2022-2028

March 2022 | 61 pages | ID: PE8722000872EN
Market Monitor Global

Abstracts

Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver.

This report contains market size and forecasts of Primary Biliary Cholangitis Therapeutics in Global, including the following market information:

Global Primary Biliary Cholangitis Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Primary Biliary Cholangitis Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

OCALIVA Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Primary Biliary Cholangitis Therapeutics include Abbott Laboratories, Allergan Plc, Eli Lilly and Co., Intercept Pharmaceuticals Inc. and Takeda Pharmaceutical Co. Ltd., etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Primary Biliary Cholangitis Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Primary Biliary Cholangitis Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Primary Biliary Cholangitis Therapeutics Market Segment Percentages, by Type, 2021 (%)

• OCALIVA
• Ursodiol
• Others

Global Primary Biliary Cholangitis Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Primary Biliary Cholangitis Therapeutics Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Private Clinic
• Other

Global Primary Biliary Cholangitis Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Primary Biliary Cholangitis Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Primary Biliary Cholangitis Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Primary Biliary Cholangitis Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Abbott Laboratories
• Allergan Plc
• Eli Lilly and Co.
• Intercept Pharmaceuticals Inc.
• Takeda Pharmaceutical Co. Ltd.

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Primary Biliary Cholangitis Therapeutics Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Primary Biliary Cholangitis Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS OVERALL MARKET SIZE

2.1 Global Primary Biliary Cholangitis Therapeutics Market Size: 2021 VS 2028
2.2 Global Primary Biliary Cholangitis Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Primary Biliary Cholangitis Therapeutics Players in Global Market
3.2 Top Global Primary Biliary Cholangitis Therapeutics Companies Ranked by Revenue
3.3 Global Primary Biliary Cholangitis Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Primary Biliary Cholangitis Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Primary Biliary Cholangitis Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Primary Biliary Cholangitis Therapeutics Players in Global Market
  3.6.1 List of Global Tier 1 Primary Biliary Cholangitis Therapeutics Companies
  3.6.2 List of Global Tier 2 and Tier 3 Primary Biliary Cholangitis Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Primary Biliary Cholangitis Therapeutics Market Size Markets, 2021 & 2028
  4.1.2 OCALIVA
  4.1.3 Ursodiol
  4.1.4 Others
4.2 By Type - Global Primary Biliary Cholangitis Therapeutics Revenue & Forecasts
  4.2.1 By Type - Global Primary Biliary Cholangitis Therapeutics Revenue, 2017-2022
  4.2.2 By Type - Global Primary Biliary Cholangitis Therapeutics Revenue, 2023-2028
  4.2.3 By Type - Global Primary Biliary Cholangitis Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Primary Biliary Cholangitis Therapeutics Market Size, 2021 & 2028
  5.1.2 Hospital
  5.1.3 Private Clinic
  5.1.4 Other
5.2 By Application - Global Primary Biliary Cholangitis Therapeutics Revenue & Forecasts
  5.2.1 By Application - Global Primary Biliary Cholangitis Therapeutics Revenue, 2017-2022
  5.2.2 By Application - Global Primary Biliary Cholangitis Therapeutics Revenue, 2023-2028
  5.2.3 By Application - Global Primary Biliary Cholangitis Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Primary Biliary Cholangitis Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Primary Biliary Cholangitis Therapeutics Revenue & Forecasts
  6.2.1 By Region - Global Primary Biliary Cholangitis Therapeutics Revenue, 2017-2022
  6.2.2 By Region - Global Primary Biliary Cholangitis Therapeutics Revenue, 2023-2028
  6.2.3 By Region - Global Primary Biliary Cholangitis Therapeutics Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Primary Biliary Cholangitis Therapeutics Revenue, 2017-2028
  6.3.2 US Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028
  6.3.3 Canada Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028
  6.3.4 Mexico Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Primary Biliary Cholangitis Therapeutics Revenue, 2017-2028
  6.4.2 Germany Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028
  6.4.3 France Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028
  6.4.4 U.K. Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028
  6.4.5 Italy Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028
  6.4.6 Russia Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028
  6.4.7 Nordic Countries Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028
  6.4.8 Benelux Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Primary Biliary Cholangitis Therapeutics Revenue, 2017-2028
  6.5.2 China Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028
  6.5.3 Japan Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028
  6.5.4 South Korea Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028
  6.5.5 Southeast Asia Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028
  6.5.6 India Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Primary Biliary Cholangitis Therapeutics Revenue, 2017-2028
  6.6.2 Brazil Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028
  6.6.3 Argentina Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Primary Biliary Cholangitis Therapeutics Revenue, 2017-2028
  6.7.2 Turkey Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028
  6.7.3 Israel Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028
  6.7.4 Saudi Arabia Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028
  6.7.5 UAE Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Abbott Laboratories
  7.1.1 Abbott Laboratories Corporate Summary
  7.1.2 Abbott Laboratories Business Overview
  7.1.3 Abbott Laboratories Primary Biliary Cholangitis Therapeutics Major Product Offerings
  7.1.4 Abbott Laboratories Primary Biliary Cholangitis Therapeutics Revenue in Global Market (2017-2022)
  7.1.5 Abbott Laboratories Key News
7.2 Allergan Plc
  7.2.1 Allergan Plc Corporate Summary
  7.2.2 Allergan Plc Business Overview
  7.2.3 Allergan Plc Primary Biliary Cholangitis Therapeutics Major Product Offerings
  7.2.4 Allergan Plc Primary Biliary Cholangitis Therapeutics Revenue in Global Market (2017-2022)
  7.2.5 Allergan Plc Key News
7.3 Eli Lilly and Co.
  7.3.1 Eli Lilly and Co. Corporate Summary
  7.3.2 Eli Lilly and Co. Business Overview
  7.3.3 Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics Major Product Offerings
  7.3.4 Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics Revenue in Global Market (2017-2022)
  7.3.5 Eli Lilly and Co. Key News
7.4 Intercept Pharmaceuticals Inc.
  7.4.1 Intercept Pharmaceuticals Inc. Corporate Summary
  7.4.2 Intercept Pharmaceuticals Inc. Business Overview
  7.4.3 Intercept Pharmaceuticals Inc. Primary Biliary Cholangitis Therapeutics Major Product Offerings
  7.4.4 Intercept Pharmaceuticals Inc. Primary Biliary Cholangitis Therapeutics Revenue in Global Market (2017-2022)
  7.4.5 Intercept Pharmaceuticals Inc. Key News
7.5 Takeda Pharmaceutical Co. Ltd.
  7.5.1 Takeda Pharmaceutical Co. Ltd. Corporate Summary
  7.5.2 Takeda Pharmaceutical Co. Ltd. Business Overview
  7.5.3 Takeda Pharmaceutical Co. Ltd. Primary Biliary Cholangitis Therapeutics Major Product Offerings
  7.5.4 Takeda Pharmaceutical Co. Ltd. Primary Biliary Cholangitis Therapeutics Revenue in Global Market (2017-2022)
  7.5.5 Takeda Pharmaceutical Co. Ltd. Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Primary Biliary Cholangitis Therapeutics Market Opportunities & Trends in Global Market
Table 2. Primary Biliary Cholangitis Therapeutics Market Drivers in Global Market
Table 3. Primary Biliary Cholangitis Therapeutics Market Restraints in Global Market
Table 4. Key Players of Primary Biliary Cholangitis Therapeutics in Global Market
Table 5. Top Primary Biliary Cholangitis Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Primary Biliary Cholangitis Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Primary Biliary Cholangitis Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Primary Biliary Cholangitis Therapeutics Product Type
Table 9. List of Global Tier 1 Primary Biliary Cholangitis Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Primary Biliary Cholangitis Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Primary Biliary Cholangitis Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Primary Biliary Cholangitis Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Primary Biliary Cholangitis Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Primary Biliary Cholangitis Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Primary Biliary Cholangitis Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Primary Biliary Cholangitis Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. Abbott Laboratories Corporate Summary
Table 31. Abbott Laboratories Primary Biliary Cholangitis Therapeutics Product Offerings
Table 32. Abbott Laboratories Primary Biliary Cholangitis Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. Allergan Plc Corporate Summary
Table 34. Allergan Plc Primary Biliary Cholangitis Therapeutics Product Offerings
Table 35. Allergan Plc Primary Biliary Cholangitis Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. Eli Lilly and Co. Corporate Summary
Table 37. Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics Product Offerings
Table 38. Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Intercept Pharmaceuticals Inc. Corporate Summary
Table 40. Intercept Pharmaceuticals Inc. Primary Biliary Cholangitis Therapeutics Product Offerings
Table 41. Intercept Pharmaceuticals Inc. Primary Biliary Cholangitis Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. Takeda Pharmaceutical Co. Ltd. Corporate Summary
Table 43. Takeda Pharmaceutical Co. Ltd. Primary Biliary Cholangitis Therapeutics Product Offerings
Table 44. Takeda Pharmaceutical Co. Ltd. Primary Biliary Cholangitis Therapeutics Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Primary Biliary Cholangitis Therapeutics Segment by Type in 2021
Figure 2. Primary Biliary Cholangitis Therapeutics Segment by Application in 2021
Figure 3. Global Primary Biliary Cholangitis Therapeutics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Primary Biliary Cholangitis Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Primary Biliary Cholangitis Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Primary Biliary Cholangitis Therapeutics Revenue in 2021
Figure 8. By Type - Global Primary Biliary Cholangitis Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Primary Biliary Cholangitis Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Primary Biliary Cholangitis Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Primary Biliary Cholangitis Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Primary Biliary Cholangitis Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Primary Biliary Cholangitis Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Primary Biliary Cholangitis Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Primary Biliary Cholangitis Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Primary Biliary Cholangitis Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. Abbott Laboratories Primary Biliary Cholangitis Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Allergan Plc Primary Biliary Cholangitis Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Intercept Pharmaceuticals Inc. Primary Biliary Cholangitis Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Takeda Pharmaceutical Co. Ltd. Primary Biliary Cholangitis Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)